CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 330 enrolled
Drug / intervention
Vilazodonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02436239
NCT02436239Phase 3Completed
CompareCT.gov

An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder

Forest Laboratories·interventional·Posted May 6, 2015·Updated Sep 11, 2019

In Brief

A Phase 3 clinical trial evaluating Vilazodone for Major Depressive Disorder. Completed, enrolled 330 participants across 56 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 6, 2015
Enrollment StartMay 2, 2015
Primary CompletionJul 23, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.2 years ago

Interventions

Vilazodonedrug

Vilazodone tablets, once daily, oral administration